CymaBay Therapeutics Inc. (NASDAQ:CBAY) has been given an average broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and two have given a strong buy rating to the company.
Analysts have set a one year consensus target price of $3.42 for the company and are anticipating that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also assigned CymaBay Therapeutics an industry rank of 185 out of 265 based on the ratings given to its competitors.
A number of research analysts recently issued reports on CBAY shares. Roth Capital started coverage on CymaBay Therapeutics in a research report on Friday, July 1st. They set a “buy” rating for the company. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, June 20th.
Shares of CymaBay Therapeutics (NASDAQ:CBAY) opened at 1.69 on Thursday. The stock’s market cap is $39.63 million. CymaBay Therapeutics has a 52 week low of $0.82 and a 52 week high of $3.04. The firm has a 50-day moving average price of $2.14 and a 200-day moving average price of $1.99.
CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.02. On average, analysts forecast that CymaBay Therapeutics will post ($1.20) earnings per share for the current fiscal year.
In other CymaBay Therapeutics news, Director Robert James Wills bought 25,000 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were purchased at an average price of $2.43 per share, with a total value of $60,750.00. Following the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at $60,750. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.00% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. BlackRock Fund Advisors increased its stake in shares of CymaBay Therapeutics by 32.1% in the second quarter. BlackRock Fund Advisors now owns 66,072 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 16,061 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of CymaBay Therapeutics by 82.3% in the first quarter. Renaissance Technologies LLC now owns 111,000 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 50,100 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of CymaBay Therapeutics by 11.4% in the second quarter. Vanguard Group Inc. now owns 612,249 shares of the biopharmaceutical company’s stock valued at $1,065,000 after buying an additional 62,896 shares during the last quarter. 30.37% of the stock is currently owned by hedge funds and other institutional investors.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.